$TSVT
2Seventy Bio Inc Stock $tsvt

$tsvt Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000186078223000038 Filed on March 16, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$41.62M	$56.18M	$91.50M
YoY Change	393.78%	250.36%	67.81%
Cost Of Revenue	$641.0K	$15.33M	$1.726M
YoY Change	25.44%	3674.63%	-31.43%
Gross Profit	$40.98M	$40.85M	$89.77M
YoY Change	417.55%	161.4%	72.62%
Gross Profit Margin	98.46%	72.72%	98.11%
Selling, General & Admin	$20.72M	$18.70M	$79.45M
YoY Change	-13.16%	-23.61%	-15.03%
% of Gross Profit	50.56%	45.78%	88.5%
Research & Development	$68.25M	$49.31M	$248.7M
YoY Change	-1.44%	-17.18%	-5.04%
% of Gross Profit	166.53%	120.71%	277.08%
Depreciation & Amortization	$2.255M	$2.325M	$11.53M
YoY Change	-36.12%	-34.23%	-29.46%
% of Gross Profit	5.5%	5.69%	12.85%
Operating Expenses	$88.97M	$68.06M	$328.2M
YoY Change	-4.45%	-18.97%	-7.67%
Operating Profit	-$51.71M	-$27.21M	-$263.1M
YoY Change	-42.91%	-60.2%	-16.18%
Interest Expense	$2.049M	$1.491M	$2.932M
YoY Change	1681.74%	1594.32%	3231.82%
% of Operating Profit
Other Income/Expense, Net	$2.643M	$2.561M	$6.055M
YoY Change	-44.5%	-64.95%	-72.03%
Pretax Income	-$47.02M	-$23.16M	-$254.2M
YoY Change	-45.14%	-62.02%	-13.02%
Income Tax	$0.00	-$17.00K	$0.00
% Of Pretax Income
Net Earnings	-$47.00M	-$23.14M	-$254.2M
YoY Change	-45.16%	-62.05%	-13.02%
Net Earnings / Revenue	-112.92%	-41.2%	-277.77%
Basic Earnings Per Share	-$1.08		-$7.13
Diluted Earnings Per Share	-$1.08	-$0.60	-$7.13
COMMON SHARES
Basic Shares Outstanding	50.19M shares	37.92M shares	35.64M shares
Diluted Shares Outstanding	43.47M shares		35.64M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$339.9M	$266.3M	$266.3M
YoY Change	-10.04%	0.46%	0.46%
Cash & Equivalents	$193.6M	$71.03M	$71.03M
Short-Term Investments	$146.3M	$195.2M	$195.2M
Other Short-Term Assets	$8.635M	$13.65M	$13.65M
YoY Change	-52.03%	43.52%	43.52%
Inventory
Prepaid Expenses	$8.635M	$13.65M
Receivables	$41.25M	$20.96M	$20.96M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$389.8M	$300.9M	$300.9M
YoY Change	-5.57%	3.2%	3.2%
LONG-TERM ASSETS
Property, Plant & Equipment	$59.15M	$55.74M	$296.6M
YoY Change	68.83%	59.64%	-4.45%
Goodwill	$12.06M	$12.06M
YoY Change	0.0%	0.0%
Intangibles	$7.125M	$7.302M
YoY Change	-18.79%	-26.18%
Long-Term Investments	$1.432M	$1.414M	$1.414M
YoY Change	-98.08%	-98.54%	-98.54%
Other Assets	$37.59M	$38.39M	$38.39M
YoY Change	-0.41%	-0.52%	-0.52%
Total Long-Term Assets	$352.6M	$355.8M	$355.8M
YoY Change	-19.7%	-24.0%	-24.0%
TOTAL ASSETS
Total Short-Term Assets	$389.8M	$300.9M	$300.9M
Total Long-Term Assets	$352.6M	$355.8M	$355.8M
Total Assets	$742.4M	$656.7M	$656.7M
YoY Change	-12.85%	-13.56%	-13.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$13.40M	$7.208M	$7.208M
YoY Change	-1.82%	19.65%	19.65%
Accrued Expenses	$55.05M	$65.84M	$65.84M
YoY Change	-19.68%	1.02%	1.02%
Deferred Revenue	$8.480M	$3.000M
YoY Change	69.6%	-40.0%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$76.93M	$79.79M	$79.79M
YoY Change	-27.64%	-18.9%	-18.9%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.401M	$2.397M	$266.4M
YoY Change	-1.23%	12.96%	-11.63%
Total Long-Term Liabilities	$2.401M	$2.397M	$266.4M
YoY Change	-1.23%	12.96%	-11.63%
TOTAL LIABILITIES
Total Short-Term Liabilities	$76.93M	$79.79M	$79.79M
Total Long-Term Liabilities	$2.401M	$2.397M	$266.4M
Total Liabilities	$341.1M	$346.2M	$346.2M
YoY Change	-15.67%	-13.42%	-13.42%
SHAREHOLDERS EQUITY
Retained Earnings	-$340.7M	-$293.6M
YoY Change	172.09%	643.52%
Common Stock	$5.000K	$4.000K
YoY Change	25.0%	100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$401.3M	$310.5M	$310.5M
YoY Change
Total Liabilities & Shareholders Equity	$742.4M	$656.7M	$656.7M
YoY Change	-12.85%	-13.56%	-13.56%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$47.00M	-$23.14M	-$254.2M
YoY Change	-45.16%	-62.05%	-13.02%
Depreciation, Depletion And Amortization	$2.255M	$2.325M	$11.53M
YoY Change	-36.12%	-34.23%	-29.46%
Cash From Operating Activities	-$49.10M	-$55.48M	-$237.1M
YoY Change	-33.74%	-3.41%	14.56%
INVESTING ACTIVITIES
Capital Expenditures	$6.079M	$3.166M	$22.84M
YoY Change	69.57%	-424.72%	97.34%
Acquisitions
YoY Change
Other Investing Activities	$50.88M	$2.634M	$34.54M
YoY Change	5.26%	-92.47%	-1.28%
Cash From Investing Activities	$44.80M	-$532.0K	$11.70M
YoY Change	0.11%	-101.56%	-24.1%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$127.1M	232.0K	$166.2M
YoY Change	-25.29%	-99.88%	-53.16%
NET CHANGE
Cash From Operating Activities	-$49.10M	-55.48M	-$237.1M
Cash From Investing Activities	$44.80M	-532.0K	$11.70M
Cash From Financing Activities	$127.1M	232.0K	$166.2M
Net Change In Cash	$122.8M	-55.78M	-$59.21M
YoY Change	-12.78%	-134.17%	-136.26%
FREE CASH FLOW
Cash From Operating Activities	-$49.10M	-$55.48M	-$237.1M
Capital Expenditures	$6.079M	$3.166M	$22.84M
Free Cash Flow	-$55.18M	-$58.65M	-$260.0M
YoY Change	-28.97%	3.86%	18.94%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001860782
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021Q3	tsvt	Common Stock Convertible Conversion Ratio CommonStockConvertibleConversionRatio	0.3333
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2022Q4	tsvt	Common Stock Convertible Conversion Ratio CommonStockConvertibleConversionRatio	0.3333
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	496765830	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	50189753	shares
CY2022	dei	Auditor Firm AuditorFirmId	42
CY2022	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2022	dei	Auditor Location AuditorLocation	Boston, Massachusetts
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	71032000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	130414000	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	195238000	usd
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	134643000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	13652000	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	9512000	usd
CY2022Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	20960000	usd
CY2021Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	16995000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	300882000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	291564000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	55735000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	34913000	usd
CY2022Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	1414000	usd
CY2021Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	97124000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	7302000	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	9892000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	12056000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	12056000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	240885000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	275534000	usd
CY2022Q4	tsvt	Restricted Cash And Other Assets Noncurrent RestrictedCashAndOtherAssetsNoncurrent	38391000	usd
CY2021Q4	tsvt	Restricted Cash And Other Assets Noncurrent RestrictedCashAndOtherAssetsNoncurrent	38592000	usd
CY2022Q4	us-gaap	Assets Assets	656665000	usd
CY2021Q4	us-gaap	Assets Assets	759675000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7208000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6024000	usd
CY2022Q4	tsvt	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	54678000	usd
CY2021Q4	tsvt	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	55410000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	11164000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	9769000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	3000000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	5000000	usd
CY2022Q4	tsvt	Collaboration Research Advancement Current CollaborationResearchAdvancementCurrent	3744000	usd
CY2021Q4	tsvt	Collaboration Research Advancement Current CollaborationResearchAdvancementCurrent	22185000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	79794000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	98388000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	5000000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	25762000	usd
CY2022Q4	tsvt	Collaboration Research Advancement Non Current CollaborationResearchAdvancementNonCurrent	0	usd
CY2021Q4	tsvt	Collaboration Research Advancement Non Current CollaborationResearchAdvancementNonCurrent	1135000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	259008000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	272446000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2397000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2122000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	346199000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	399853000	usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.1000
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.1000
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	37928000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	37928000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23585000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23585000	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	4000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	606986000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	400026000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2877000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-712000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-293647000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-39494000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	310466000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	359822000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	656665000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	759675000	usd
CY2022	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	32358000	usd
CY2021	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	26921000	usd
CY2020	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	115594000	usd
CY2022	us-gaap	Revenues Revenues	91496000	usd
CY2021	us-gaap	Revenues Revenues	54522000	usd
CY2020	us-gaap	Revenues Revenues	248122000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	248735000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	252617000	usd
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	296467000	usd
CY2022	tsvt	Manufacturing Costs Under Commercial Arrangements ManufacturingCostsUnderCommercialArrangements	14851000	usd
CY2021	tsvt	Manufacturing Costs Under Commercial Arrangements ManufacturingCostsUnderCommercialArrangements	9320000	usd
CY2020	tsvt	Manufacturing Costs Under Commercial Arrangements ManufacturingCostsUnderCommercialArrangements	0	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	79450000	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	93506000	usd
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	90897000	usd
CY2021	tsvt	Income Loss From Collaborative Arrangements IncomeLossFromCollaborativeArrangements	-10071000	usd
CY2020	tsvt	Income Loss From Collaborative Arrangements IncomeLossFromCollaborativeArrangements	0	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-263140000	usd
CY2022	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	2932000	usd
CY2021	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	88000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	6055000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	21647000	usd
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	18056000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-254153000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-292213000	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-120114000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-254153000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-292213000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-120114000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-7.13
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-7.13
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-12.44
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-12.44
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.14
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.14
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	35637000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	35637000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23499000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23499000	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23369000	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23369000	shares
CY2022	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	usd
CY2021	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	usd
CY2020	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-2165000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-712000	usd
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	0	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-2165000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-712000	usd
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	0	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-256318000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-292925000	usd
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-120114000	usd
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	43692000	usd
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	60997000	usd
CY2020	tsvt	Transfers From Transfers To Net Parent Investment TransfersFromTransfersToNetParentInvestment	90054000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-120114000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	74629000	usd
CY2021	tsvt	Share Based Payment Arrangement Increase For Cost Recognition From Parent ShareBasedPaymentArrangementIncreaseForCostRecognitionFromParent	44626000	usd
CY2021	tsvt	Transfers From Transfers To Net Parent Investment TransfersFromTransfersToNetParentInvestment	517706000	usd
CY2021	tsvt	Stock Issued During Period Value Consummation Of Spin Off Transaction StockIssuedDuringPeriodValueConsummationOfSpinOffTransaction	0	usd
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	6544000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-292213000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	359822000	usd
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	2000	shares
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	17000	usd
CY2022	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	13934000	shares
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	165533000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	41040000	usd
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	372000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2165000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-254153000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	310466000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-254153000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-292213000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-120114000	usd
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	232000	usd
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	439000	usd
CY2020	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-6468000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	11533000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	16350000	usd
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	13188000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	41040000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	54629000	usd
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	60997000	usd
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-85000	usd
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-430000	usd
CY2020	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-73000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	8356000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1578000	usd
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1526000	usd
CY2022	tsvt	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	34649000	usd
CY2021	tsvt	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	15541000	usd
CY2020	tsvt	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	13764000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	327000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-6000	usd
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-13240000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-8110000	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	15733000	usd
CY2020	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-7479000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-12042000	usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-16199000	usd
CY2020	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-10960000	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-22762000	usd
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	4180000	usd
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	8317000	usd
CY2022	tsvt	Increase Decrease In Collaboration Research Advancement IncreaseDecreaseInCollaborationResearchAdvancement	19577000	usd
CY2021	tsvt	Increase Decrease In Collaboration Research Advancement IncreaseDecreaseInCollaborationResearchAdvancement	7496000	usd
CY2020	tsvt	Increase Decrease In Collaboration Research Advancement IncreaseDecreaseInCollaborationResearchAdvancement	7397000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-237134000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-207034000	usd
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-67793000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	22842000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	11575000	usd
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	22261000	usd
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	145908000	usd
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	usd
CY2020	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	180447000	usd
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	34986000	usd
CY2020	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	usd
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	8000000	usd
CY2020	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	11697000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	15411000	usd
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-22261000	usd
CY2022	us-gaap	Proceeds From Contributions From Parent ProceedsFromContributionsFromParent	0	usd
CY2021	us-gaap	Proceeds From Contributions From Parent ProceedsFromContributionsFromParent	354889000	usd
CY2020	us-gaap	Proceeds From Contributions From Parent ProceedsFromContributionsFromParent	90054000	usd
CY2022	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	165533000	usd
CY2021	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	usd
CY2020	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	usd
CY2022	tsvt	Proceeds From Stock Options Exercised And Stock Plans ProceedsFromStockOptionsExercisedAndStockPlans	696000	usd
CY2021	tsvt	Proceeds From Stock Options Exercised And Stock Plans ProceedsFromStockOptionsExercisedAndStockPlans	0	usd
CY2020	tsvt	Proceeds From Stock Options Exercised And Stock Plans ProceedsFromStockOptionsExercisedAndStockPlans	0	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	166229000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	354889000	usd
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	90054000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-59208000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	163266000	usd
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	0	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	163266000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	usd
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	104058000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	163266000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	71032000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	130414000	usd
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	0	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	33026000	usd
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	32852000	usd
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	0	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	10896000	usd
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	3703000	usd
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2039000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	4989000	usd
CY2022	tsvt	Noncash Or Part Noncash Transfer To Net Parent Investment NoncashOrPartNoncashTransferToNetParentInvestment	0	usd
CY2021	tsvt	Noncash Or Part Noncash Transfer To Net Parent Investment NoncashOrPartNoncashTransferToNetParentInvestment	110300000	usd
CY2020	tsvt	Noncash Or Part Noncash Transfer To Net Parent Investment NoncashOrPartNoncashTransferToNetParentInvestment	0	usd
CY2022	tsvt	Increase Of Right Of Use Asset And Associated Lease Liability Due To Reassessment IncreaseOfRightOfUseAssetAndAssociatedLeaseLiabilityDueToReassessment	0	usd
CY2021	tsvt	Increase Of Right Of Use Asset And Associated Lease Liability Due To Reassessment IncreaseOfRightOfUseAssetAndAssociatedLeaseLiabilityDueToReassessment	174618000	usd
CY2020	tsvt	Increase Of Right Of Use Asset And Associated Lease Liability Due To Reassessment IncreaseOfRightOfUseAssetAndAssociatedLeaseLiabilityDueToReassessment	0	usd
CY2022	us-gaap	Stock Issued1 StockIssued1	0	usd
CY2021	us-gaap	Stock Issued1 StockIssued1	6544000	usd
CY2020	us-gaap	Stock Issued1 StockIssued1	0	usd
CY2022	us-gaap	Nature Of Operations NatureOfOperations	Description of the business<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2seventy bio, Inc. (the “Company” or “2seventy bio”) is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The Company’s approach combines its expertise in T cell engineering technology and lentiviral vector gene delivery approaches, experience in research, development, and manufacturing of cell therapies and a suite of technologies that can be selectively deployed to develop highly innovative, targeted cellular therapies for patients with cancer. The Company is advancing multiple preclinical and clinical programs in oncology and, together with Bristol Myers Squibb (“BMS”), delivering the first FDA-approved CAR T therapy in multiple myeloma, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Abecma</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (idecabtagene vicleucel, or ide-cel), to patients in the United States. Please refer to Note 10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative arrangements and strategic partnerships</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the collaboration with BMS. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2seventy bio Securities Corporation is a wholly-owned subsidiary of the Company which was incorporated in Massachusetts on December 13, 2021 and was granted securities corporation status in Massachusetts for the 2021 tax year. 2seventy bio Securities Corporation has no employees.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks and uncertainties similar to other companies in the biotechnology industry. There can be no assurance that the Company’s preclinical studies and clinical trials will be successfully completed, that it will maintain protection of proprietary technology, or that it will obtain the necessary government regulatory approvals for its product candidates or those of its collaborators. Even if approved, these product candidates may not be commercially viable. The Company operates in an environment of rapid technological innovation and substantial competition from pharmaceutical and biotechnology companies. Additionally, the Company is dependent on key personnel and on third party organizations such as financial institutions, collaborators, and contract manufacturing organizations. </span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The separation from bluebird bio, Inc.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, bluebird bio, Inc. (“bluebird bio”) announced its plans to separate its oncology portfolio and programs from its severe genetic disease portfolio and programs, and spin off its oncology portfolio and programs into a separate, publicly traded company. In furtherance of this plan, 2seventy bio was incorporated as a Delaware corporation in April 2021, and in September 2021, bluebird bio’s board of directors approved the distribution of all of the issued and outstanding shares of 2seventy bio common stock on the basis of one share of 2seventy bio common stock for every three shares of bluebird bio common stock issued and outstanding on October 19, 2021, the record date for the distribution. As a result of the distribution, which occurred on November 4, 2021, 2seventy bio became an independent, publicly traded company.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 3, 2021, the Company also entered into a separation agreement with bluebird bio, which is referred to in this annual report as the “Separation Agreement”, as well as various other agreements with bluebird bio, including a tax matters agreement, an employee matters agreement, an intellectual property license agreement, a transition services agreement under which 2seventy bio temporarily receives certain services from bluebird bio, and a second transition services agreement under which 2seventy bio temporarily provides certain services to bluebird bio. These agreements also govern certain of 2seventy bio’s relationships with bluebird bio after the separation. For additional information regarding the Separation Agreement and the other related agreements, refer to Note 14, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-party transactions.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Going concern</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Accounting Standards Codification (“ASC”) 205-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Going Concern</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the date that the consolidated and combined financial </span></div>statements are issued. The Company has incurred losses and has experienced negative operating cash flows for all historical periods presented. During the year ended December 31, 2022, the Company incurred a net loss of $254.2 million and used $237.1 million of cash in operations. The Company expects to continue to generate operating losses and negative operating cash flows for the next few years. The Company's continued operations are dependent on its ability to raise additional funding. <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the Company had cash, cash equivalents and marketable securities of $267.7 million. In January 2023, the Company entered into a Share Purchase Agreement with Regeneron Pharmaceuticals, Inc. (“Regeneron”) pursuant to which it sold 1,114,827 shares of its common stock to Regeneron for an aggregate cash price of approximately $20.0 million. In March 2023, the Company sold 10.9 million shares of common stock through an underwritten public offering at a price per share of $11.50. This resulted in aggregate gross proceeds to the Company of approximately $125.0 million, before deducting underwriting discounts and commissions and offering expenses. Based on its current operating plans, including with respect to the ongoing commercialization of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Abecma</span>, the Company expects that its cash, cash equivalents and marketable securities (including amounts received from the transactions discussed above), will be sufficient to fund current planned operations for at least the next twelve months from the date of filing this Annual Report on Form 10-K. The Company may, in the future, pursue additional cash resources through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances or licensing arrangements with third parties. This includes the potential sale of shares of its common stock of up to $150.0 million in gross proceeds under the at-the-market (“ATM”) facility established in November 2022 with Cowen and Company, LLC. No sales of common stock have occurred under this ATM as of the date of this Annual Report on Form 10-K.
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-254200000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-237100000	usd
CY2022Q4	tsvt	Cash Cash Equivalents And Marketable Securities CashCashEquivalentsAndMarketableSecurities	267700000	usd
CY2021	us-gaap	Proceeds From Contributions From Parent ProceedsFromContributionsFromParent	354900000	usd
CY2021Q4	tsvt	Spinoff Transaction Recognized Identifiable Assets Acquired And Liabilities Assumed Net SpinoffTransactionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet	384500000	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimates and judgments are used in the following areas, among others: allocations of revenue, expenses, assets and liabilities from bluebird bio's historical consolidated financial statements to the Company for periods prior to the separation, future undiscounted cash flows and subsequent fair value estimates used to assess potential and measure any impairment of long-lived assets, including goodwill and intangible assets, the measurement of right-of-use assets and lease liabilities, contingent consideration, stock-based compensation expense, accrued expenses, income taxes, and the assessment of the Company's ability to fund its operations for at least the next twelve months from the date of issuance of these financial statements. In addition, estimates and judgments are used in the Company’s accounting for its revenue-generating arrangements, in particular as it relates to determining the stand-alone selling price of performance obligations, evaluating whether an option to acquire additional goods and services represents a material right, estimating the total transaction price, including estimating variable consideration and the probability of achieving future potential development and regulatory milestones, assessing the period of performance over which revenue may be recognized, and accounting for modifications to revenue-generating arrangements.</span></div>
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	565000	usd
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of credit risk and off-balance sheet risk</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that subject the Company to credit risk primarily consist of cash and cash equivalents, available-for-sale securities, and accounts receivable. Deposits are maintained with banks in the United States and such amounts may exceed the amount of insurance provided on such deposits. The Company has not experienced any losses on such accounts, and does not believe it is exposed to any unusual credit risk beyond the normal credit risk currently associated with commercial banking relationships. Cash deposits are insured by the Federal Deposit Insurance Corporations (“FDIC”) up to $250,000. The Company has cash deposits in excess of the FDIC insured limit. The Company’s marketable securities, which primarily consist of U.S. government agency securities and treasuries, corporate bonds and commercial paper, potentially subject the Company to concentrations of credit risk. </span></div>The Company has adopted an investment policy that limits the amounts the Company may invest in any one type of investment and requires all investments held by the Company to be at least AA+/Aa1 rated, thereby reducing credit risk exposure. The Company’s accounts receivable balance primarily consists of amounts owed from collaborative arrangement partners and royalties receivable under out-license agreements with various third parties. The Company monitors economic conditions to identify facts or circumstances that may indicate that any of its accounts receivable are at risk of collection.
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	0	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	0	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	160130000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	565000	usd
CY2022Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	0	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3416000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	8794000	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	54678000	usd
CY2022	tsvt	Contract With Customer Liability Revenue Recognized Including Opening Balance ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance	32358000	usd
CY2021	tsvt	Contract With Customer Liability Revenue Recognized Including Opening Balance ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance	26921000	usd
CY2020	tsvt	Contract With Customer Liability Revenue Recognized Including Opening Balance ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance	115594000	usd
CY2022Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	13094000	usd
CY2021Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	6768000	usd
CY2022Q4	tsvt	Accrued Clinical And Contract Research Organization Costs Current AccruedClinicalAndContractResearchOrganizationCostsCurrent	1619000	usd
CY2021Q4	tsvt	Accrued Clinical And Contract Research Organization Costs Current AccruedClinicalAndContractResearchOrganizationCostsCurrent	3229000	usd
CY2022Q4	tsvt	Accrued Collaboration Research Costs Current AccruedCollaborationResearchCostsCurrent	2005000	usd
CY2021Q4	tsvt	Accrued Collaboration Research Costs Current AccruedCollaborationResearchCostsCurrent	2576000	usd
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	0	shares
CY2022Q4	tsvt	Accrued Property Plant And Equipment Current AccruedPropertyPlantAndEquipmentCurrent	1498000	usd
CY2021Q4	tsvt	Accrued Property Plant And Equipment Current AccruedPropertyPlantAndEquipmentCurrent	2241000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	239000	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1688000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	198754000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	6000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	2108000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	196652000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	232332000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	565000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	231767000	usd
CY2022Q4	us-gaap	Interest Receivable InterestReceivable	300000	usd
CY2021Q4	us-gaap	Interest Receivable InterestReceivable	400000	usd
CY2021	tsvt	Interest Receivable Write Off InterestReceivableWriteOff	0	usd
CY2022	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	91385000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	278000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	88674000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	1830000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	180059000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	2108000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	160130000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	103573000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	74991000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	47838000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	40078000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	55735000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	34913000	usd
CY2022	us-gaap	Depreciation Depreciation	8900000	usd
CY2021	us-gaap	Depreciation Depreciation	12100000	usd
CY2020	us-gaap	Depreciation Depreciation	9400000	usd
CY2022Q4	tsvt	Accrued Manufacturing Costs Current AccruedManufacturingCostsCurrent	17962000	usd
CY2021Q4	tsvt	Accrued Manufacturing Costs Current AccruedManufacturingCostsCurrent	5459000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	14845000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	24655000	usd
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	55410000	usd
CY2022	tsvt	Salary And Wage Bonus Payout Period SalaryAndWageBonusPayoutPeriod	P6M
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	33738000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	24838000	usd
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	22454000	usd
CY2022	us-gaap	Lease Cost LeaseCost	33738000	usd
CY2021	us-gaap	Lease Cost LeaseCost	24838000	usd
CY2020	us-gaap	Lease Cost LeaseCost	22454000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	27140000	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	25489000	usd
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	19632000	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P10Y9M18D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P11Y9M18D
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y4M24D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0547
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0547
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0672
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	43900000	usd
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	34500000	usd
CY2020	us-gaap	Operating Lease Expense OperatingLeaseExpense	32500000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	27861000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	28672000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	29498000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	32920000	usd
CY2022Q4	tsvt	Lessee Operating Lease Liability To Be Paid Year Five And Thereafter LesseeOperatingLeaseLiabilityToBePaidYearFiveAndThereafter	250383000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	369334000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	99162000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	270172000	usd
CY2020	tsvt	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	0.003
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.025
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0.003
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.041
CY2022Q4	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	16008000	usd
CY2022Q4	us-gaap	Purchase Obligation Due In Second Year PurchaseObligationDueInSecondYear	15750000	usd
CY2022Q4	us-gaap	Purchase Obligation Due In Third Year PurchaseObligationDueInThirdYear	0	usd
CY2022Q4	tsvt	Purchase Obligation To Be Paid Year Four And Thereafter PurchaseObligationToBePaidYearFourAndThereafter	0	usd
CY2022Q4	us-gaap	Purchase Obligation PurchaseObligation	31758000	usd
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q4	tsvt	Common Stock Number Of Votes Per Common Share CommonStockNumberOfVotesPerCommonShare	1	vote
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	37900000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	37900000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23600000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23600000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	6689000	shares
CY2021Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	5686000	shares
CY2022	tsvt	Effective Income Tax Rate Reconciliation Tax Credits Research And Development EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment	0.032
CY2021	tsvt	Effective Income Tax Rate Reconciliation Tax Credits Research And Development EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment	0.002
CY2020	tsvt	Effective Income Tax Rate Reconciliation Tax Credits Research And Development EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment	0.138
CY2022	tsvt	Effective Income Tax Rate Reconciliation Officer Compensation Limitation EffectiveIncomeTaxRateReconciliationOfficerCompensationLimitation	-0.012
CY2021	tsvt	Effective Income Tax Rate Reconciliation Officer Compensation Limitation EffectiveIncomeTaxRateReconciliationOfficerCompensationLimitation	-0.004
CY2020	tsvt	Effective Income Tax Rate Reconciliation Officer Compensation Limitation EffectiveIncomeTaxRateReconciliationOfficerCompensationLimitation	-0.016
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Contingencies EffectiveIncomeTaxRateReconciliationTaxContingencies	-0.002
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	38600000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	31298000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	7302000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	38600000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	28708000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	9892000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2600000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4300000	usd
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3800000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	708000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	708000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	708000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	708000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	708000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	3762000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	7302000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost	1500000	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost	1300000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	41000000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	54600000	usd
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	61000000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	41040000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	54629000	usd
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	60997000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Contingencies EffectiveIncomeTaxRateReconciliationTaxContingencies	0
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Contingencies EffectiveIncomeTaxRateReconciliationTaxContingencies	-0.011
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.006
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.011
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.013
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	41040000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	54629000	usd
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	60997000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.789
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M6D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.018
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested	5500000	usd
CY2021Q4	tsvt	Number Of Transition Services Agreements NumberOfTransitionServicesAgreements	2	agreement
CY2021Q4	tsvt	Transition Services Agreement Initial Term TransitionServicesAgreementInitialTerm	P2Y
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.274
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.648
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.321
CY2022	tsvt	Effective Income Tax Rate Reconciliation Spin Off Adjustment Percent EffectiveIncomeTaxRateReconciliationSpinOffAdjustmentPercent	0
CY2021	tsvt	Effective Income Tax Rate Reconciliation Spin Off Adjustment Percent EffectiveIncomeTaxRateReconciliationSpinOffAdjustmentPercent	-0.854
CY2020	tsvt	Effective Income Tax Rate Reconciliation Spin Off Adjustment Percent EffectiveIncomeTaxRateReconciliationSpinOffAdjustmentPercent	0
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	3200000	usd
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	2400000	usd
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	2200000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-254153000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-292213000	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-120114000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	0	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	0	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	0	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-254153000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-292213000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-120114000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.066
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.006
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.038
CY2022	tsvt	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.002
CY2021	tsvt	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	0
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	27251000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	12142000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	10071000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	466000	usd
CY2022Q4	tsvt	Deferred Tax Assets Capitalized License Fee And Research And Development Expenses DeferredTaxAssetsCapitalizedLicenseFeeAndResearchAndDevelopmentExpenses	11888000	usd
CY2021Q4	tsvt	Deferred Tax Assets Capitalized License Fee And Research And Development Expenses DeferredTaxAssetsCapitalizedLicenseFeeAndResearchAndDevelopmentExpenses	11905000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	3237000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	13724000	usd
CY2022Q4	tsvt	Deferred Tax Assets Stock Based Compensation DeferredTaxAssetsStockBasedCompensation	16719000	usd
CY2021Q4	tsvt	Deferred Tax Assets Stock Based Compensation DeferredTaxAssetsStockBasedCompensation	15824000	usd
CY2022Q4	tsvt	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	73719000	usd
CY2021Q4	tsvt	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	71941000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	3857000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	5395000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	55719000	usd
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	202461000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	131397000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	0	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	476000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	65181000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	69693000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	9266000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	2958000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	128014000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	58270000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	69700000	usd
CY2022	tsvt	Capitalized Research And Development Expense CapitalizedResearchAndDevelopmentExpense	232100000	usd
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4403000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	36000	usd
CY2021	tsvt	Unrecognized Tax Benefits Decrease Resulting From Gross Spin Off Adjustment UnrecognizedTaxBenefitsDecreaseResultingFromGrossSpinOffAdjustment	4403000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	36000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	713000	usd
CY2022	tsvt	Unrecognized Tax Benefits Decrease Resulting From Gross Spin Off Adjustment UnrecognizedTaxBenefitsDecreaseResultingFromGrossSpinOffAdjustment	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	749000	usd
CY2022Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0	usd
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3911000	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2570000	shares
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0	shares

Files In Submission

Name	View Source	Status
0001860782-23-000038-index-headers.html	Edgar Link	pending
0001860782-23-000038-index.html	Edgar Link	pending
0001860782-23-000038.txt	Edgar Link	pending
0001860782-23-000038-xbrl.zip	Edgar Link	pending
a2seventybio-arbylawsfinal.htm	Edgar Link	pending
eyconsentexhibit2311.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
gpswitzerland-severanceagr.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nheffronconsultingagreemen.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tsvt-20221231.htm	Edgar Link	pending
tsvt-20221231.xsd	Edgar Link	pending
tsvt-20221231_g1.jpg	Edgar Link	pending
tsvt-q410xkex311leschly1.htm	Edgar Link	pending
tsvt-q410xkexhibit312baird1.htm	Edgar Link	pending
tsvt-q4202210xkexhibit2111.htm	Edgar Link	pending
tsvt-q4202210xkexhibit3211.htm	Edgar Link	pending
tsvt-20221231_htm.xml	Edgar Link	completed
tsvt-20221231_lab.xml	Edgar Link	unprocessable
tsvt-20221231_def.xml	Edgar Link	unprocessable
tsvt-20221231_pre.xml	Edgar Link	unprocessable
tsvt-20221231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TSVT
2Seventy Bio Inc Stock $tsvt

2023 Q1 Form 10-K Financial Statement

#000186078223000038 Filed on March 16, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TSVT 2Seventy Bio Inc Stock $tsvt

2023 Q1 Form 10-K Financial Statement

#000186078223000038 Filed on March 16, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TSVT
2Seventy Bio Inc Stock $tsvt